Letter by Reddy et al Regarding Article, “Cannabis Use and Outcomes in Patients With Aneurysmal Subarachnoid Hemorrhage”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the article by Behrouz et al.1 In light of recent movements for widespread legalization of recreational marijuana, the adverse effects of cannabis remain a pressing area of research. Behrouz et al1 present a retrospective cohort analysis of 213 patients with aneurysmal subarachnoid hemorrhage (aSAH), of whom 25.9% tested positive for cannabinoids (CB+). The authors noted that CB+ aSAH had an increased risk of delayed cerebral ischemia.
Behrouz et al1 claim to be the first to investigate the incidence of cannabis use in patients with aSAH and its impact on patient outcomes. However, we recently published a similar study2 utilizing the Nationwide …